Figure 5. HumAb 3D1-MMAE ADCs are active against human tumor models.

(A and B) HCT116/vector (A; blue circles), HCT116/MUC1 (A; red diamonds), and HCC827 (B) cells were incubated with the indicated concentrations of humAb 3D1-MMAE ADCs. (C) ZR-75-1 cells were incubated with the indicated concentrations of humAb 3D1-MMAE ADCs (red squares), mAb 3D1-MMAE ADCs (green diamonds), or mAb CD1-MMAE ADCs (blue circles). Percentage viability was determined by Alamar blue. (D) Nude mice bearing ZR-75-1 tumor xenografts (~200 mm³) were pair matched and then treated i.v. with vehicle control (blue circles) or humAb 3D1-MMAE ADCs at a dose of 5 mg/kg/wk for 3 weeks (red squares). The results are expressed as tumor volumes (mean ± SEM; 6 mice per group). (E) NCG mice bearing PDX TNBC tumor xenografts (~150 mm³) were pair matched and then treated i.v. with vehicle control (blue circles) or humAb 3D1-MMAE ADCs at a dose of 5 mg/kg/wk for 3 weeks (red squares). The results are expressed as tumor volumes (mean ± SEM; 6 mice per group).